데일리리치앤드럭키

This is a randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy, safety, and pharmacokinetics of FNP-223 (oral formulation) in slowing the progression of progressive supranuclear palsy (PSP)
The study is being conducted across 44 centers in the European Union, the United Kingdom, and the United States
The study reinforces Ferrer’s commitment to researching and developing transformative therapeutic solutions for people with rare neurological diseases

Spanish international pharmaceutical company Ferrer has announced the completion of patient recruitment for the PROSPER study, a Phase II clinical trial designed to assess the efficacy, safety, and pharmacokinetics of FNP-223, an orally available, potent and selective inhibitor of the OGA enzyme, in-licensed from Asceneuron, aimed at slowing disease progression in Progressive Supranuclear Palsy (PSP)[1].

PSP is a rare, rapidly progressive and ultimately fatal neurodegenerative disease[2]. To date, no disease-modifying therapies have been approved for PSP.

The PROSPER study is a randomized, double-blind, placebo-controlled trial[3] that has successfully recruited the planned number of 220 participants with PSP in just 14 months, achieving this milestone on October 6th, two months ahead of schedule. A total of 44 centers across the European Union, the United Kingdom, and the United States are participating. The study design includes a six-week screening period, followed by 52 weeks’ treatment with either FNP-223 or placebo and a subsequent four-week follow-up period after the completion of treatment[3].

The study focuses on participants with early-stage progressive supranuclear palsy-Richardson syndrome (PSP-RS), a critical stage during which early intervention may have the greatest impact on slowing disease progression. Identifying the disease at this stage is a significant challenge due to its rapid progression and diagnostic complexity, making the achievement of this recruitment milestone ahead of schedule even more meaningful.

Prof. Dr. Med. G